EVM
RXRX icon

Eaton Vance Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Eaton Vance Management’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-200
Closed -$3K – 2529
2021
Q4 		$3K Hold
200
– – ﹤0.01% 2708
2021
Q3 		$5K Hold
200
– – ﹤0.01% 1818
2021
Q2 		$7K Buy
+200
New +$5.92K ﹤0.01% 2600

Other funds holding RXRX

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OMS
Obvious Management Services San Francisco, California $42.4M AUM 54.5% 1-Year Est. Return
DCI
Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Eaton Vance Management's RXRX Position: Q1 2022 in Review

Eaton Vance Management sold out of Recursion Pharmaceuticals (RXRX) in Q1 2022, closing a stake of 200 shares — an estimated $3K sold.

Eaton Vance Management first reported a position in RXRX in Q2 2021 and held it in 3 quarters. The position peaked at $7K in Q2 2021. 128 funds tracked by Wall St. Rank hold RXRX as of Q1 2022.

  • Eaton Vance Management reported no remaining Recursion Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 200 Recursion Pharmaceuticals shares in Q1 2022, an estimated $3K.
  • Eaton Vance Management first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 3 quarters.
  • Eaton Vance Management's Recursion Pharmaceuticals position peaked at $7K in Q2 2021.
  • 128 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.